RB1
RB1 encodes the Retinoblastoma protein, the foundational tumor suppressor that acts as the "master brake" for the cell cycle. By physically locking the transcription factors needed for DNA replication, it prevents uncontrolled division; its inactivation is a universal requirement for the development of most human cancers and a defining feature of cellular senescence.
Key Takeaways
- •RB1 is the master brake of the cell cycle, ensuring that cells only divide when conditions are perfect.
- •In its active state, RB1 physically "locks up" E2F, the messenger needed to start DNA replication.
- •Virtually all cancers find a way to disable the RB1 brake, either by mutating the gene or over-activating its inhibitors (CDKs).
- •RB1 is the switch that forces a cell into "senescence" (aging), stopping it from becoming cancerous but contributing to the aging of the body.
- •CDK4/6 inhibitors, a major class of modern cancer drugs, work by keeping the RB1 brake in the "on" position.
Basic Information
- Gene Symbol
- RB1
- Full Name
- RB Transcriptional Corepressor 1
- Also Known As
- pRbRBp105-RbPPP1R130
- Location
- 13q14.2
- Protein Type
- Transcriptional corepressor
- Protein Family
- Pocket protein family
Related Isoforms
The canonical full-length protein that regulates the G1/S transition.
Key SNPs
Germline mutation associated with hereditary retinoblastoma; disrupts the pocket domain.
Nonsense mutation leading to a truncated, non-functional RB protein.
Found in several retinoblastoma families; affects E2F binding affinity.
Recurrent truncating mutation in the large pocket region.
Mutant that cannot be phosphorylated by CDKs, yet remains non-functional.
Mutation in the promoter region that reduces RB1 expression levels.
Overview
RB1 (Retinoblastoma 1) is the founding member of the tumor suppressor gene family. It encodes the RB protein, a critical gatekeeper that sits at the "Restriction Point"—the point of no return where a cell decides whether to remain quiet or commit to the massive task of dividing into two. Because of this central role, RB1 is one of the most important guardians of the human genome.
The function of RB1 is controlled through a process called phosphorylation. In a healthy, resting cell, RB1 has very few phosphate groups attached to it (hypophosphorylation), allowing it to bind and silence the E2F family of growth-promoting factors. When the cell receives growth signals, kinases (CDK4/6) add multiple phosphates to RB1, causing it to release its grip on E2F and letting the cell cycle proceed. In cancer, this brake is either physically broken or permanently "pushed down" by overactive kinases.
Conceptual Model
A simplified mental model for the pathway:
In cancer, the brake is either physically broken or the hand (CDK) is pushing it down forever.
Core Health Impacts
- • G1/S Control: Master control of the G1/S cell cycle checkpoint and DNA replication entry.
- • Differentiation: Critical for tissue differentiation and the timing of developmental programs.
- • Tumor Suppression: Essential tumor suppressor; loss is a required step in many human cancers.
- • Senescence Lock: Maintains cellular senescence and prevents oncogenic transformation.
- • Genome Security: Prevents the replication of damaged DNA, preserving genome integrity.
Protein Domains
Pocket Domain
The functional core (A/B subdomains); forms the docking site for E2F and viral proteins.
C-Terminal Tail
Contains multiple phosphorylation sites that act as a tuning dial for RB1 activity.
N-Terminal Domain
Involved in protein stability and the formation of higher-order chromatin complexes.
Upstream Regulators
p16INK4a Activator
CDK inhibitor that keeps RB1 in its active, growth-suppressive state.
PP1 Phosphatase Activator
Dephosphorylates RB1 at the end of mitosis, resetting the brake.
DNA Damage (p53/p21) Activator
Stress signals that induce p21 to inhibit CDKs, preventing RB1 inactivation.
Cell Contact Inhibition Activator
Signals from neighboring cells that keep RB1 active to prevent overcrowding.
Serum Starvation Activator
Lack of growth factors prevents CDK activation, keeping RB1 bound to E2F.
Downstream Targets
E2F1 / E2F2 / E2F3 Inhibits
Transcription factors that drive the S-phase program; physically inhibited by active RB1.
Cyclin E Inhibits
Essential for S-phase entry; transcriptionally repressed by the RB1-E2F complex.
PCNA Inhibits
DNA polymerase clamp required for replication; regulated by RB1-controlled E2F factors.
DHFR Inhibits
Enzyme involved in nucleotide synthesis; an S-phase gene repressed by RB1.
Chromatin Modifiers (HDACs) Activates
RB1 recruits these to promoters to shut down gene expression through silencing.
Caspase-3 Modulates
RB1 can influence apoptotic sensitivity through both transcriptional and non-transcriptional mechanisms.
Role in Aging
RB1 is a cornerstone of the "Senescence" program, which is one of the primary drivers of biological aging. While it protects us from cancer in youth, its persistent activation in old age leads to the accumulation of dysfunctional "zombie" cells.
Cellular Senescence
Active RB1 is required to lock cells in a permanent state of growth arrest, preventing cancer but driving aging.
Stem Cell Quiescence
RB1 maintains stem cells in a quiet, protected state. Loss of this control can lead to stem cell exhaustion.
Epigenetic Aging
By recruiting HDACs and DNMTs, RB1 shapes the epigenetic landscape; changes here contribute to age-related drift.
Metabolic Resilience
RB1 influences adipogenesis and mitochondrial function; declines are associated with shifts in muscle and fat.
Genome Stability
By enforcing strict S-phase entry, RB1 prevents the replication of damaged DNA, preserving the genome.
Regenerative Capacity
The balance between RB1 activity (safety) and CDK activity (growth) determines how well an organism can repair.
Disorders & Diseases
Retinoblastoma
A childhood eye cancer defining the gene. Loss of both RB1 copies leads to uncontrolled retinal cell growth.
Small Cell Lung Cancer
Loss of RB1 and TP53 is a near-universal requirement for this extremely aggressive and rapidly dividing tumor.
Breast Cancer
In luminal breast cancers, the RB1 pathway is often functionally disabled by CDK4/6 overactivity.
HPV-Related Cancers
The HPV E7 oncoprotein physically binds and degrades RB1, bypassing the cell cycle brake.
Osteosarcoma
RB1 loss is a frequent driver in bone tumors, reflecting its role in regulating mesenchymal precursors.
Interventions
Supplements
Soy isoflavone studied for its potential to modulate the CDK/RB pathway in laboratory models.
May influence the expression of p21 and other upstream regulators of RB1 activity.
Green tea extract reported to inhibit CDK activity, potentially keeping RB1 in its active state.
Lifestyle
Reduces the systemic drive for cell division, supporting the maintenance of the RB1 brake.
Improves metabolic health and insulin/IGF-1 levels, which are upstream drivers of CDK activity.
The cell cycle is tightly linked to circadian rhythms; sleep supports normal checkpoint regulation.
Reduces the burden of DNA damage that could otherwise lead to the selection of RB1-deficient clones.
Medicines
CDK4/6 inhibitor that prevents RB1 phosphorylation, keeping the brake on in breast cancer.
Potent CDK4/6 inhibitor used to maintain RB1 activity and block S-phase entry in cancer cells.
Selective inhibitor of CDK4 and CDK6; prevents the inactivation of the RB protein.
Often used in RB1-deficient tumors which can be highly sensitive to DNA-damaging agents.
Lab Tests & Biomarkers
Genetic Status
Required for screening families at risk for hereditary retinoblastoma.
Detects deletions of the 13q14 locus in oncology samples using NGS.
In pathology, high p16 is often a proxy for RB1 loss due to feedback failure.
Activity Markers
High levels (hyperphosphorylated) indicate the brake is OFF and the cell is dividing.
General marker of cell proliferation; correlates with the inactivation of RB1.
Research marker; measures the expression levels of S-phase genes.
Hormonal Interactions
Estrogen Indirect Inactivator
Signals to upregulate Cyclin D1, which activates CDKs to phosphorylate and disable RB1.
Insulin / IGF-1 Growth Stimulus
Promotes the transition from G1 to S phase by activating the RB1 inactivation pathway.
Growth Hormone Indirect Regulator
Influences the systemic levels of growth factors that drive the cell cycle machinery.
Cortisol Cycle Modulator
Glucocorticoids can induce p21 expression in some tissues, supporting RB1 activity.
Deep Dive
Network Diagrams
RB1 Molecular Brake Mechanism
The G1/S Transition Circuit
The Pocket Mechanism: How RB1 Silences the Genome
The “Pocket” of the RB protein is one of the most studied structural motifs in biology. It is not just a passive physical block; it is an active silencing machine.
- E2F Neutralization: The pocket domain (A/B region) has a high affinity for the activation domain of E2F. By binding to it, RB1 hides E2F from the rest of the transcription machinery, essentially “deafening” the genes that need E2F to turn on.
- Epigenetic Reinforcement: RB1 goes further by recruiting Histone Deacetylases (HDACs) to the promoter. These enzymes remove the chemical tags that keep DNA “open,” causing the chromatin to bundle up tightly. This ensures that the cell cycle genes are not just inhibited, but epigenetically locked.
The CDK-RB Axis: The Pulse of Life
Every time a cell divides, it performs a high-stakes calculation focused entirely on RB1.
- Phosphorylation Cascade: In early G1 phase, Cyclin D-CDK4/6 complexes begin adding a few phosphate groups to RB1 (hypophosphorylation). This is a “warning” to the cell. As growth signals intensify, Cyclin E-CDK2 complexes add many more phosphates (hyperphosphorylation).
- The Point of No Return: Once RB1 reaches a critical threshold of phosphorylation, it undergoes a massive shape change and releases E2F. This is known as the Restriction Point. Beyond this point, the cell will finish dividing even if growth factors are removed.
RB1 and the Paradox of Senescence
RB1 is the switch that forces a cell into Cellular Senescence. When a cell detects that it is too damaged to safely divide, it engages RB1 to lock its DNA forever.
This is a double-edged sword. In a young person, senescence prevents cancer by stopping damaged cells from multiplying. But as we get older, these “senescent” cells accumulate in our tissues. Because they are still metabolically active, they secrete inflammatory signals (SASP) that damage surrounding healthy cells. RB1 is thus the primary architect of both our safety from tumors and our gradual decline into old age.
Interpreting RB1 Status
CDK4/6 Sensitivity. For CDK4/6 inhibitors to work, the RB1 protein must be intact. If the brake is missing, these drugs will not work.
The p16 Inverse Marker. Seeing very high levels of p16 protein in a tumor is often a sign that the RB1 brake is missing.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
One of the first studies to isolate and characterize the RB1 protein product.
Seminal review establishing RB1 as the master regulator of the G1/S transition.
Discovered the p16-CDK-RB pathway as a central axis in human cancer.
Detailed exploration of the complex interactions between RB1 and the E2F family.
Early evidence that RB1 loss is a significant factor beyond retinoblastoma.
Comprehensive review of how targeting the RB1 axis has become a major clinical strategy.